Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study

Randomized Controlled Trial

doi: 10.1111/adb.12012. Epub 2012 Dec 12.

Tagrid Lemenager, Sabine Hoffmann, Iris Reinhard, Derik Hermann, Anil Batra, Michael Berner, Norbert Wodarz, Andreas Heinz, Michael N Smolka, Ulrich S Zimmermann, Stefan Wellek, Falk Kiefer, Raymond F Anton; PREDICT Study Team

Affiliations

PMID: 23231446
DOI: 10.1111/adb.12012

Randomized Controlled Trial

Karl Mann et al. Addict Biol. 2013 Nov.

Abstract

The results of placebo-controlled trials (RCTs) with acamprosate or naltrexone vary substantially. Those differences have been attributed to differing patient characteristics, recruitment strategies, treatment settings and remuneration systems. We tested these assumptions by comparing a new double-blind, placebo-controlled randomized trial conducted in Germany (called PREDICT Study) with data from the US COMBINE Study. PREDICT was designed according to the protocol of the COMBINE Study. A total of 426 alcohol-dependent patients were compared to 459 COMBINE Study patients corresponding to the treatment cells in PREDICT. All patients received acamprosate, naltrexone or placebo for 3 months (PREDICT) or 4 months (COMBINE). Biweekly manualized 'medical management' to enhance compliance was delivered in both studies. Time until the first occurrence of heavy drinking was the main outcome measure. PREDICT found neither acamprosate nor naltrexone to supply any additional benefit compared with placebo, which is at variance with a positive naltrexone effect being reported in the COMBINE Study. A secondary comparison between both studies showed better overall treatment outcomes in PREDICT, although these patients had been more severely affected than their COMBINE counterparts. The divergence in results may be attributable to basic differences in the treatment environments (such as in-patient pre-treatment versus primary outpatient care). We suggest that identically designed RCTs conducted in different parts of the world may help improve the external validity of RCTs. This approach could be called 'comparative efficacy research'.

Trial registration: ClinicalTrials.gov NCT00317031.

Keywords: Acamprosate; alcohol addiction; combine study; naltrexone; predict study; randomized placebo-controlled trial.

PubMed Disclaimer

Cited by

Advances in the science and treatment of alcohol use disorder.
Witkiewitz K, Litten RZ, Leggio L. Witkiewitz K, et al. Sci Adv. 2019 Sep 25;5(9):eaax4043. doi: 10.1126/sciadv.aax4043. eCollection 2019 Sep. Sci Adv. 2019. PMID: 31579824 Free PMC article. Review.
Study Protocol for a Randomized Double Blind, Placebo Controlled Trial Exploring the Effectiveness of a Micronutrient Formula in Improving Symptoms of Anxiety and Depression.
Blampied M, Bell C, Gilbert C, Boden J, Nicholls R, Rucklidge JJ. Blampied M, et al. Medicines (Basel). 2018 Jun 14;5(2):56. doi: 10.3390/medicines5020056. Medicines (Basel). 2018. PMID: 30720786 Free PMC article.
Emerging concepts in alcoholic hepatitis.
Fung P, Pyrsopoulos N. Fung P, et al. World J Hepatol. 2017 Apr 28;9(12):567-585. doi: 10.4254/wjh.v9.i12.567. World J Hepatol. 2017. PMID: 28515843 Free PMC article. Review.
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.
Springer SA, Altice FL, Herme M, Di Paola A. Springer SA, et al. Contemp Clin Trials. 2014 Mar;37(2):209-18. doi: 10.1016/j.cct.2013.12.006. Epub 2013 Dec 31. Contemp Clin Trials. 2014. PMID: 24384538 Free PMC article. Clinical Trial.
[Nalmefene: a novel pharmacotherapeutic option for alcoholism].
Soyka M. Soyka M. Nervenarzt. 2014 May;85(5):578-82. doi: 10.1007/s00115-013-3843-3. Nervenarzt. 2014. PMID: 24126432 Review. German.

Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study - PubMed (original) (raw)